Supernus to Present at Two Investor Conferences in September ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in September 2013: Rodman & Renshaw: Presentation Date: Monday, September 9 Time: 11:40am ET Place: Millennium Broadway Hotel, NY Stifel Nicolaus Weisel: Presentation Date: Thursday, September 12 Time:1:30pm ET Place: Four Seasons Hotel, Boston, MA About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD. CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591
Supernus to Present at Two Investor Conferences in September
Press spacebar to pause and continue. Press esc to stop.